BioNTech SE (BNTX)
After hours:
| Previous Close | 99.25 |
| Open | 100.64 |
| Bid | 99.83 x 800 |
| Ask | 101.91 x 900 |
| Day's Range | 99.28 - 103.41 |
| 52 Week Range | 88.00 - 188.99 |
| Volume | |
| Avg. Volume | 632,914 |
| Market Cap | 24.075B |
| Beta (5Y Monthly) | 0.24 |
| PE Ratio (TTM) | 5.27 |
| EPS (TTM) | 19.04 |
| Earnings Date | Nov 06, 2023 |
| Forward Dividend & Yield | 2.11 (1.32%) |
| Ex-Dividend Date | Jun 02, 2022 |
| 1y Target Est | 140.34 |
Yahoo FinanceAWS expands big pharma partnerships in manufacturing, AI, and R&D
Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.
- Reuters
CORRECTED-UPDATE 1-European Patent Office declares Moderna mRNA patent invalid
The European Patent Office declared a contested mRNA patent owned by Moderna invalid, the office said on Tuesday, handing a win to BioNTech and its partner Pfizer in a patent dispute between the two coronavirus vaccine makers. Moderna said in a statement that it disagreed with the office's decision and would lodge an appeal. Shares in Moderna were down 2.3% in premarket trading on Wall Street after the decision was announced by BioNTech earlier on Tuesday.
- Reuters
BioNTech says European Patent Office has declared Moderna patent invalid
COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by BioNTech and its partner Pfizer. "We understand and welcome the European Patent Office’s decision to revoke Moderna’s European Patent 3 718 565 B1," the German biotech firm said in a statement. "The European Patent Office’s decision is an important one as we believe that this and others of Moderna’s patents do not meet the requirements for grant and should never have been granted," it added.
